Last reviewed · How we verify

Durvalumab + Chemotherapy phase

AstraZeneca · Phase 3 active Small molecule

Durvalumab + Chemotherapy phase is a PD-L1 inhibitor Small molecule drug developed by AstraZeneca. It is currently in Phase 3 development for Unresectable stage III non-small cell lung cancer (NSCLC) with concurrent chemotherapy and radiation, Metastatic or unresectable gastric/gastroesophageal junction adenocarcinoma, Biliary tract cancer. Also known as: Chemotherapy phase.

Durvalumab blocks PD-L1 to restore anti-tumor immunity, combined with chemotherapy to enhance tumor cell killing.

Durvalumab blocks PD-L1 to restore anti-tumor immunity, combined with chemotherapy to enhance tumor cell killing. Used for Unresectable stage III non-small cell lung cancer (NSCLC) with concurrent chemotherapy and radiation, Metastatic or unresectable gastric/gastroesophageal junction adenocarcinoma, Biliary tract cancer.

At a glance

Generic nameDurvalumab + Chemotherapy phase
Also known asChemotherapy phase
SponsorAstraZeneca
Drug classPD-L1 inhibitor
TargetPD-L1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Durvalumab is a PD-L1 inhibitor that prevents tumor cells from suppressing the immune system, allowing T cells to recognize and attack cancer. When combined with chemotherapy, the chemotherapy damages tumor cells and increases their immunogenicity, while durvalumab simultaneously removes the immune checkpoint brake, creating a synergistic anti-tumor effect.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Durvalumab + Chemotherapy phase

What is Durvalumab + Chemotherapy phase?

Durvalumab + Chemotherapy phase is a PD-L1 inhibitor drug developed by AstraZeneca, indicated for Unresectable stage III non-small cell lung cancer (NSCLC) with concurrent chemotherapy and radiation, Metastatic or unresectable gastric/gastroesophageal junction adenocarcinoma, Biliary tract cancer.

How does Durvalumab + Chemotherapy phase work?

Durvalumab blocks PD-L1 to restore anti-tumor immunity, combined with chemotherapy to enhance tumor cell killing.

What is Durvalumab + Chemotherapy phase used for?

Durvalumab + Chemotherapy phase is indicated for Unresectable stage III non-small cell lung cancer (NSCLC) with concurrent chemotherapy and radiation, Metastatic or unresectable gastric/gastroesophageal junction adenocarcinoma, Biliary tract cancer.

Who makes Durvalumab + Chemotherapy phase?

Durvalumab + Chemotherapy phase is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

Is Durvalumab + Chemotherapy phase also known as anything else?

Durvalumab + Chemotherapy phase is also known as Chemotherapy phase.

What drug class is Durvalumab + Chemotherapy phase in?

Durvalumab + Chemotherapy phase belongs to the PD-L1 inhibitor class. See all PD-L1 inhibitor drugs at /class/pd-l1-inhibitor.

What development phase is Durvalumab + Chemotherapy phase in?

Durvalumab + Chemotherapy phase is in Phase 3.

What are the side effects of Durvalumab + Chemotherapy phase?

Common side effects of Durvalumab + Chemotherapy phase include Fatigue, Nausea, Decreased appetite, Diarrhea, Immune-mediated pneumonitis, Immune-mediated hepatitis.

What does Durvalumab + Chemotherapy phase target?

Durvalumab + Chemotherapy phase targets PD-L1 and is a PD-L1 inhibitor.

Related